Financial Gravity Asset Management, Inc. Corcept Therapeutics Inc Transaction History

Financial Gravity Asset Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	SELL	$19.95 - $29.96 $7,900 - $11,864	-396 Reduced 95.19%	20 $650,000
Q3 2022 Nov 03, 2022	BUY	$24.7 - $29.12 $10,275 - $12,113	416 New	416 $2.21 Million
Q2 2021 Aug 11, 2021	SELL	$19.97 - $24.43 $2,476 - $3,029	-124 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$23.49 - $30.56 $892 - $1,161	38 Added 44.19%	124 $2.96 Million
Q4 2020 Feb 16, 2021	BUY	$16.78 - $27.3 $1,443 - $2,347	86 New	86 $2,000

473

80.2M

596K

710K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $8.09B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.